Search results for "ST elevation"

showing 10 items of 84 documents

Metformin and contrast-induced acte kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevati…

2016

IF 4.638; International audience; AIM : To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI).METHODS: Patients with type 2 diabetes mellitus (T2DM) treated with PCI 27μmol/l (0.3mg/dl) or >50% over baseline after PCI. Since PCI was urgent, metformin could not be withheld prior to PCI but was usually stopped after PCI.RESULTS:Among the 372 patients included, 147 (40%) were using metformin, which had older diabetes, but had risk factors similar to patients without metformin. Baseline eGFR was better in pati…

Malemedicine.medical_specialtyendocrine system diseasesMedication Therapy Managementmedicine.medical_treatmentStatistics as TopicContrast Media030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessment03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedbusiness.industryPrimary percutaneous coronary interventionAcute kidney injuryPercutaneous coronary interventionnutritional and metabolic diseasesMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseST segment elevation segment myocardial infarctionMetformin3. Good healthMetforminAcute kidney injuryDiabetes Mellitus Type 2CreatinineConventional PCICardiologyST Elevation Myocardial InfarctionFemaleFranceCardiology and Cardiovascular MedicinebusinessKidney diseasemedicine.drug
researchProduct

Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study

2020

Altres ajuts: Conselleria d'Educació, Investigació, Cultura i Esport GV/2018/116 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40…

Malemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemLeft ventricular ejection fractionCardiac magnetic resonancemedicine.medical_treatmentMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme InhibitorsPilot Projects030204 cardiovascular system & hematologyVentricular Function LeftPCSK9Angiotensin Receptor Antagonists03 medical and health sciences0302 clinical medicineCardiac magnetic resonance imagingOriginal Research ArticlesInternal medicinemedicineST‐segment elevation myocardial infarctionHumansST segmentOriginal Research Article030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedKillip classEjection fractionmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionStroke VolumeMiddle Agedmedicine.diseaseST-segment elevation myocardial infarctionlcsh:RC666-701Heart failureCardiologyST Elevation Myocardial InfarctionProprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Prognostic Value of New-Generation Troponins in ST-Segment-Elevation Myocardial Infarction in the Modern Era: The RUTI-STEMI Study.

2017

Background In ST ‐segment–elevation myocardial infarction ( STEMI ), troponins are not needed for diagnosis: symptoms and ECG data are sufficient to activate percutaneous coronary intervention. This study explored the prognostic value of new‐generation troponins in a real‐life cohort contemporarily treated for STEMI . Methods and Results We studied 1260 consecutive patients with primary STEMI treated with percutaneous coronary intervention between February 22, 2011, and August 31, 2015. We collected data on clinical characteristics and major adverse cardiovascular and cerebrovascular events ( MACCEs ) at 30 days and 1 year. Peak high‐sensitivity troponin T and sensitive‐contemporary tropon…

Malemedicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyCoronary AngiographyVentricular Function Left03 medical and health sciencesElectrocardiography0302 clinical medicinePercutaneous Coronary InterventionPredictive Value of TestsIschemiaInternal medicineCardiovascular DiseaseST segmentMedicineHumansCoronary Heart Disease030212 general & internal medicineMyocardial infarctionST‐segment–elevation myocardial infarctionAgedRetrospective StudiesOriginal ResearchAged 80 and overbiologybusiness.industrytroponinPercutaneous coronary interventionMiddle Agedmedicine.diseasePrognosisTroponinmyocardial infarctionbiology.proteinCardiologyST Elevation Myocardial InfarctionFemaleMortality/SurvivalCardiology and Cardiovascular MedicinebusinessValue (mathematics)BiomarkersJournal of the American Heart Association
researchProduct

Lipoprotein(a) and long-term recurrent infarction after an episode of ST-segment elevation acute myocardial infarction

2020

Background In established ischemic heart disease, the relationship between lipoprotein(a) and new cardiovascular events showed contradictory results. Our aim was to assess the relationship between lipoprotein(a) and very long-term recurrent myocardial infarction (MI) after an index episode of ST-segment elevation acute myocardial infarction (STEMI). Methods We included 435 consecutive STEMI patients discharged from October 2000 to June 2003 in a single teaching center. The relationship between lipoprotein(a) at discharge and recurrent MI was evaluated through negative binomial regression and Cox regression analysis. Results The mean age was 65 years (55-74 years), 25.5% were women, 34.7% we…

Malemedicine.medical_specialtymedicine.medical_treatmentInfarction030204 cardiovascular system & hematologyRate ratio03 medical and health sciences0302 clinical medicineRecurrenceInternal medicineFibrinolysismedicineRisk of mortalityHumansST segment030212 general & internal medicineMyocardial infarctionAgedRetrospective Studiesbiologybusiness.industryIncidenceGeneral MedicineLipoprotein(a)Middle Agedmedicine.diseaseConfidence intervalSpainbiology.proteinCardiologyST Elevation Myocardial InfarctionFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesForecastingLipoprotein(a)Coronary Artery Disease
researchProduct

Five-Year Survival in Patients With ST-Segment–Elevation Myocardial Infarction According to Modalities of Reperfusion Therapy

2014

Background— Although primary percutaneous coronary intervention (pPCI) is the preferred reperfusion method for ST-segment–elevation myocardial infarction, it remains difficult to implement in many areas, and fibrinolytic therapy is still widely used. Methods and Results— We assessed 5-year mortality in patients with ST-segment–elevation myocardial infarction from the French Registry of Acute ST-Elevation or Non-ST Elevation Myocardial Infarction (FAST-MI) 2005 according to use and type of reperfusion therapy. Of 1492 patients with ST-segment–elevation myocardial infarction with a first call ≤12 hours from onset, 447 (30%) received fibrinolysis (66% prehospital; 97% with subsequent angiogra…

Malemedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionMyocardial Reperfusion030204 cardiovascular system & hematologyCohort Studies03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineReperfusion therapyFibrinolytic AgentsPhysiology (medical)Internal medicineFibrinolysisHumansMedicineST segmentRegistries030212 general & internal medicineMyocardial infarctionAgedAged 80 and overbusiness.industryST elevationHazard ratioPercutaneous coronary interventionMiddle Agedmedicine.disease3. Good healthSurgerySurvival RateTreatment OutcomeConventional PCICardiologyFemaleFranceCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Cell-free DNA and Microvascular Damage in ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.

2019

INTRODUCTION AND OBJECTIVES Cell-free DNA (cfDNA) in ST-segment elevation myocardial infarction might originate from hyperactivated leukocytes at the coronary lesion. Our aim was to investigate the relationship between cfDNA and coronary reperfusion. METHODS We studied 116 patients treated with primary angioplasty using thrombus aspiration. Coronary (during aspiration) and peripheral (at the end of the procedure) blood samples were drawn for cfDNA, as well as high-sensitivity troponin T and myeloperoxidase quantification. The primary endpoint was no ST-segment resolution (STR) (≥ 70%) and the secondary endpoint was lack of final Thrombolysis In Myocardial Infarction flow 3 (TIMI 3). RESULTS…

Malemedicine.medical_specialtymedicine.medical_treatmentMyocardial ReperfusionMyocardial Reperfusion Injury030204 cardiovascular system & hematologyLymphocyte ActivationLesion03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionTroponin TInternal medicinemedicineClinical endpointLeukocytesST segmentHumanscardiovascular diseasesMyocardial infarctionProspective StudiesPeroxidaseTroponin Tbusiness.industryPercutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedmedicine.diseaseTreatment OutcomeMicrovesselsCardiologyST Elevation Myocardial InfarctionFemalemedicine.symptombusinessCell-Free Nucleic AcidsTIMIRevista espanola de cardiologia (English ed.)
researchProduct

Assessment of quality of care of patients with ST-segment elevation myocardial infarction

2020

Aims:The 2017 European Society of Cardiology guidelines for the management of ST-elevation myocardial infarction recommended assessing quality of care to establish measurable quality indicators in order to ensure that every ST-elevation myocardial infarction patient receives the best possible care. We investigated the quality indicators of healthcare services in Poland provided to ST-elevation myocardial infarction patients.Methods and results:The Polish Registry of Acute Coronary Syndromes is a nationwide, multicentre, prospective study of acute coronary syndrome patients in Poland. For the purpose of assessing quality indicators, we included 8279 patients from the Polish Registry of Acute…

Malemedicine.medical_specialtymedicine.medical_treatmentacute myocardial infarctionQuality indicatorshealthcare system performance030204 cardiovascular system & hematologyCoronary AngiographyCritical Care and Intensive Care MedicineElectrocardiography03 medical and health sciences0302 clinical medicineReperfusion therapyPatient Self-ReportRisk FactorsOutcome Assessment Health CareHumansMedicineST segmentProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionQuality of careAgedQuality of Health CareEjection fractionbusiness.industryPercutaneous coronary interventionGeneral MedicineMiddle Agedmedicine.diseasemortalityHeart failureEmergency medicineST Elevation Myocardial InfarctionFemaleCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal. Acute Cardiovascular Care
researchProduct

Long-term outcomes in men and women with ST-segment elevation myocardial infarction and incomplete reperfusion after a primary percutaneous coronary …

2019

Background The failure of reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI) is more frequent than considered previously. Aim To evaluate sex-related differences in long-term outcomes in patients with STEMI and incomplete infarct-related artery reperfusion after a primary percutaneous coronary intervention. Patients and methods Of consecutive 42 752 patients with STEMI hospitalized between 2009 and 2011 in Poland, we analyzed a group of 766 (35%) women and 1453 (65%) men with less than thrombolysis in myocardial infarction (TIMI) flow grade 3 following a primary percutaneous coronary intervention. Results In the 2-year follow-up, the mortality rate among…

Malesex differencesTime Factorsmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematology0302 clinical medicineRisk FactorsPrevalenceRegistriesTreatment Failure030212 general & internal medicineMyocardial infarctionStrokeAged 80 and overIncidenceMortality rateHazard ratioGeneral MedicineMiddle Agedprimary percutaneous coronary interventionCardiologyFemaleCardiology and Cardiovascular Medicinelong-term outcomesTIMImedicine.medical_specialtyPatient ReadmissionRisk Assessment03 medical and health sciencesPercutaneous Coronary InterventionSex FactorsReperfusion therapyCoronary CirculationInternal medicinemedicineHumanscardiovascular diseasesAgedHeart Failurebusiness.industryPercutaneous coronary interventionHealth Status Disparitiesmedicine.diseaseST-segment elevation myocardial infarctionincomplete reperfusionHeart failureST Elevation Myocardial InfarctionPolandbusinessCoronary Artery Disease
researchProduct

Cardiovascular magnetic resonance characterization of a hamartoma in an asyntomatic child

2009

Abstract Background The prevalence of primary cardiac neoplasms is approximately 0.3% and these masses should be distinguished from many of other primary and secondary processes that can occur in the heart. Further assessment of the left ventricular mass presents important clinical implications. Cardiovascular magnetic resonance was used. Clinical case An asyntomatic 12-year-old child was referred for cardiovascular magnetic resonance imaging to further assess a left ventricular mass found after an echocardiography, executed for assessment for sport activity. His past medical history was absolutely negative. The patient was in optimal state of health. The EKG showed an aspecific ST elevatio…

Past medical historymedicine.medical_specialtySurgical approachmedicine.diagnostic_testbusiness.industryST elevationCardiac NeoplasmMagnetic resonance imagingmedicine.diseaseLeft ventricular massmedicineHamartomaRadiologyClinical caseCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Differences in Symptomatology and Clinical Course of Acute Coronary Syndromes in Women ≤45 Years of Age Compared to Older Women

2021

Acute coronary syndromes (ACS) in young people are rare. The data regarding differences in symptoms in relation to age are scarce, which may have an influence on outcomes. The aim of this study was to evaluate the differences in the clinical course of ACS between younger women (≤45 years old) and older women (63-64 years old). We compared 7481 women with ACS from the Polish Registry of ACS between 2007 and 2014 (1834 women aged ≤45 years and 5647 women aged 63-64 years). The predominant symptom of ACS in both groups was chest pain, with a higher incidence occurring in younger women (90.4% vs 88.5%, P = 0.025). Prehospital cardiac arrest occurred more often in younger women (2.1% vs 0.8%, P0…

Pediatricsmedicine.medical_specialtyAdolescentMEDLINE030204 cardiovascular system & hematologyChest pain03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinemedicineHumans030212 general & internal medicineAcute Coronary SyndromeAgedbusiness.industryIncidence (epidemiology)Age FactorsClinical courseGeneral MedicineMiddle AgedCoronary VesselsTreatment OutcomeST Elevation Myocardial InfarctionFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessCurrent Problems in Cardiology
researchProduct